Payment overview · 2025
General Payments
$644.22
29 reported records · 14 companies
Healthcare provider profile · identity verified
Larry Bergere, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FAYETTEVILLE, GA · NPI 1609966613
Verified facts
What the public records show
CMS Open Payments records show Larry Bergere, M.D. received $644.22 in general payments during 2025 across 29 reported records.
SANOFI-AVENTIS U.S. LLC accounted for 16.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ozempic by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $103.02 | 16.0% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $96.53 | 15.0% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $95.61 | 14.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.10 | 7.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $48.58 | 7.5% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.15 | 6.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $41.66 | 6.5% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$37.22 | 5.8% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $33.65 | 5.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.51 | 3.8% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $24.39 | 3.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.77 | 2.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.54 | 2.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $13.49 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $644.22 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $103.02 | 6 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $95.61 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $81.36 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $81.36 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $44.15 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $41.66 | 2 | 2025 |
Source payment records
|
|||||
| INTERSTIM Normalized: interstim |
Device | Medtronic, Inc. | $37.22 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $35.25 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $33.65 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $27.95 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.51 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $24.39 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.63 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.77 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.77 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.85 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 135 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
135 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 805 | 250 |
| Atorvastatin Calcium | Atorvastatin Calcium | 614 | 198 |
| Hydrochlorothiazide | Hydrochlorothiazide | 417 | 135 |
| Levothyroxine Sodium | Levothyroxine Sodium | 366 | 107 |
| Losartan Potassium | Losartan Potassium | 351 | 101 |
| Metformin Hcl | Metformin Hcl | 336 | 103 |
| Simvastatin | Simvastatin | 253 | 72 |
| Lisinopril | Lisinopril | 200 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 185 | 61 |
| Alprazolam | Alprazolam | 175 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 173 | 59 |
| Omeprazole | Omeprazole | 148 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 144 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 144 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 139 | 64 |
| Jardiance | Empagliflozin | 135 | 30 |
| Glimepiride | Glimepiride | 134 | 37 |
| Tramadol Hcl | Tramadol Hcl | 129 | 30 |
| Carvedilol | Carvedilol | 128 | 39 |
| Prednisone | Prednisone | 125 | 88 |
| Gabapentin | Gabapentin | 121 | 42 |
| Sertraline Hcl | Sertraline Hcl | 118 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 111 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 109 | 37 |
| Hydralazine Hcl | Hydralazine Hcl | 108 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 98 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 91 | 38 |
| Nifedipine Er | Nifedipine | 90 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 89 | 80 |
| Furosemide | Furosemide | 89 | 30 |
| Allopurinol | Allopurinol | 87 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 86 | 24 |
| Famotidine | Famotidine | 85 | 34 |
| Januvia | Sitagliptin Phosphate | 79 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 25 |
| Clonazepam | Clonazepam | 74 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 22 |
| Eliquis | Apixaban | 69 | 23 |
| Montelukast Sodium | Montelukast Sodium | 66 | 22 |
| Atenolol | Atenolol | 63 | 19 |
| Potassium Chloride | Potassium Chloride | 63 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 14 |
| Memantine Hcl | Memantine Hcl | 53 | 19 |
| Lovastatin | Lovastatin | 52 | 12 |
| Ezetimibe | Ezetimibe | 51 | 17 |
| Tradjenta | Linagliptin | 51 | 14 |
| Ketoconazole | Ketoconazole | 48 | 27 |
| Glipizide | Glipizide | 47 | 14 |
| Benazepril Hcl | Benazepril Hcl | 45 | 13 |
| Finasteride | Finasteride | 43 | 14 |
| Lorazepam | Lorazepam | 42 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 42 | 14 |
| Fenofibrate | Fenofibrate | 38 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 13 |
| Alendronate Sodium | Alendronate Sodium | 35 | 14 |
| Valsartan | Valsartan | 35 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Glipizide Er | Glipizide | 32 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 30 | 11 |
| Meloxicam | Meloxicam | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Verapamil Er | Verapamil Hcl | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | 11 |
| Hydrocortisone | Hydrocortisone | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 24 |
| Clonidine Hcl | Clonidine Hcl | 27 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | 11 |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Mupirocin | Mupirocin | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 11 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 16 |
| Diazepam | Diazepam | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Jantoven | Warfarin Sodium | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Uloric | Febuxostat | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $644.22 · 29 records | SANOFI-AVENTIS U.S. LLC | AREXVY, BREZTRI, Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE 3, INTERSTIM, JARDIANCE, Kerendia, Korlym, LEQVIO, OTEZLA, Ohtuvayre, Omnipod, Ozempic, REPATHA, Rybelsus, SHINGRIX, TZIELD, The Cologuard Plus Collection Kit, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error